In this editorial, David H. Ilson, M.D., Ph.D., provides insight into the global trial CheckMate 577 involving patients with esophageal adenocarcinoma and squamous-cell carcinoma.

Now Online The principles of directed cell migration dlvr.it/RzfgYT

🎉 Breaking news 🎉 The USPSTF has officially lowered the recommended age to begin #CRC screening to age 45! Check out our editorial in JAMA below! Dana-Farber's Young-Onset Colorectal Cancer Center Dana-Farber Dana-Farber News Fola May, MD PhD jamanetwork.com/journals/jama/…

What Type of Immune Cell are You? bit.ly/3dzRxiQ

Super excited to present at my first live #ASCO22 #womeninoncology #ASCOWNC Thank you for all my mentors and asco buddy Maria Garcia-Jimenez, MD MHS

Overall, CheckMate 722 is another negative study but the subsets and landmark PFS rates suggest some patients may benefit. We are not currently able to identify them so we need better biomarkers or better combinations in this space. #ESMOAsia22

Amazingly comprehensive data from the UK 100,000 cancer genomes project- 100,000 likes from me!

Landed in Chicago with my cofellow Shuai Wang !!✈️🛬 Excited for #ASCO24💃💃 Hem-Onc Fellows Network Montefiore Health System #isthishowyoutag??

#ASCOLung How it started How it is going

What an amazing night w our extended Montefiore Health System Albert Einstein College of Medicine - Official family incl a Giant of Onc ranging from ‘86 (yes- The Sparanos!) to just abt starting Michael Sandhu, MD And the icing on the cake -or gulab jamun 🇮🇳was seeing the amazing success of 4 of our prior thoracic mentees!

Spot our rockstar attendings 🤩Montefiore Health System Albert Einstein College of Medicine - Official Balazs Halmos Carolina Bernabe Fernand Bteich @Dr.Kaubisch And our amazing past, current, future fellows💜 Ece Cali Daylan, MD, PhD Shuai Wang Fernand Bteich Michael Sandhu, MD #ASCO24

LAURA Ph 3: Osimertinib vs Placebo #ASCO24 ASCO ➡️ mPFS: 39.1 vs 5.6 mo (HR 0.16) ‼️ ➡️ 24-mo PFS: 65% vs 13% 📈 ➡️ 81% received osi at progression 💊, Good! ➡️AE discontinuation**: 13% vs 5% ⚠️ Can't wait for Suresh S. Ramalingam, MD, FASCO's presentation today! 🎤 #ASCO24 OncoAlert Data

Thoughtful and insightful discussion on practice changing LAURA results by Dr. Sequist Lecia Sequist, MD, MPH. 👏 Molecular profiling is critical. Can we identify a small subset of patients who are candidates for de-escalation? #ASCO24

Dr. David R. Spigel, MD, FASCO presents Phase III ADRIATIC study at #ASCO24: consolidation durvalumab x 2y after chemoradiation for limited stage #SCLC. Balanced arms. >50% with PCI. Mostly daily radiation delivered.

Wow. This news .... needs to be Amplified worldwide!!! 🫁

Excellent work by Angelica D'Aiello, MD (let me also introduce her as incoming Montefiore Health System faculty!), Shayan Nazari Caris Life Sciences, Hyein Jeon, MD Haiying Cheng on a mol analysis of alternate checkpoints in NSCLC! This project is Angelica’s baby-but as she is also a new mom-a close 2nd one👶

Grateful for the opportunity!! Thank you for your guidance! I learned a lot through this paper!! And yes!! I am looking for a job in DC/Maryland/Northern VA! 🤗

Feels way more complicated than this (esp with TKI/sequencing) but a 2024 #NSCLC management algorithm for boards #lcsm #MedTwitter #OncTwitter

To take the right care of a patient with lung cancer takes a village! This is our Montefiore Health System Albert Einstein College of Medicine - Official village! #ArthurAvenue #Bronx Brendon Stiles Nitin Ohri Chirag Shah MD Ali Sadoughi Steven Vogl Neel Chudgar, MD